Specifically, based on their results assessing IDH mutations associated with ATRX and H3K27me3, immunostainings can help to determine the necessity of 1p/19q codeletion testing in IDH-mutant gliomas [75]. The gene discussed is ATRX; the disease is central nervous system cancer.